Fox  2004.

Study characteristics
Methods	Design: Randomised cross‐over study Setting: UK; two centres Recruitment: 3 May to 31 May 2002 Number screened: 27 Number randomised:  14 Outcome timing: 2 weeks
Participants	Tremor in MS Inclusion criteria: diagnosis of definite MS (Poser 1983), age between 18 and 64 years, and a visible upper limb tremor Exclusion criteria: cognitive impairment; history of ischaemic heart disease or psychotic illness, or unwilling to stop driving for the period of the study Randomised: N = 14; % female: 57.1;  mean age: 45 (range: 35 to 56) years; mean EDSS: 6.25 (range: 3.5 to 7.5);  previous cannabis use: 1 participant
Interventions	Cannador versus placebo.  Cannador is an ethanolic extract of cannabis sativa standardised to 2.5 mg of THC per capsule.  Identical placebo capsule. In a titration phase the dose was escalated at 3‐day intervals until either the patient reached a maximum dose of 0.125 mg/kg of THC twice a day or they began to experience intolerable side effects, in which case the dose was dropped to the last tolerated dose. Study duration: 2 x2 weeks treatment periods. No washout Concomitant medication during the study: NR
Outcomes	Tremor: change on a tremor index, measured using a validated tremor rating scale Spasticity: not assessed Pain: not assessed PGIC: not assed HRQoL: not assessed Serious AEs: NR AEs: N/phase Dizziness: N/phase Somnolence: N/phase
Notes	Funding: public. One author was funded by a grant from the Medical Research Council